Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

Inclusion Criteria: 1. Patients over 18 years of age 2. Patients who understands the process of clinical study and voluntarily signs a peer letter 3. Visit1: A person whose blood pressure measured in visit1 corresponds to the following conditions * Blood pressure medication taken patients: 130mmHg ≤ sitSBP\<180mmHg, sitDBP\<110mmHg * Blood pressure medication free patients: 140mmHg ≤ sitSBP\<180mmHg, sitDBP\<110mmHg 4. Visit2: 140mmHg ≤ sitSBP\<180mmHg, sitDBP\<110mmHg or if patients are in high risk group: 130mmHg ≤ sitSBP \<180mmHg, sit DBP \< 110mmHg Exclusion Criteria: * Difference in mean value of blood pressure measured in both arms of more than 20mmHg in sitSBP or more than 10mmHg in sitDBP * Orthostatic hypotension with symptoms within 3months of visit 1 * Secondary hypertensive patient or suspected to be * Uncontrolled diabetes mellitus(HbA1c \> 9%) or type I diabetes mellitus * Active gout or hyperuricemia (uric acid ≥ 9mg/dL) * Severe heart disease or severe neurovascular disease * Severe or malignant retinopathy * Clinically significant hematological finding * Severe renal diseases (eGFR\<30mL/min/1.73m2) * Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times) * Hypokalemia or Hyperkalemia(K\<3.5mmol/L or K ≥ 5.5mmol/L) * Hyponatremia or Hypernatremia(Na\<135mmol/L or Na ≥ 155mmol/L) * Hypercalcemia * History of malignancy tumor * History of autoimmune disease * History of alcohol or drug abuse * Positive to pregnancy test, nursing mother, intention on pregnancy * Considered by investigator as not appropriate to participate in the clinical study with othe reason